BSE Live
Dec 26, 14:16Prev. Close
1212.65
Open Price
1206.20
Bid Price (Qty.)
1209.10 (10)
Offer Price (Qty.)
1210.10 (14)
NSE Live
Dec 26, 14:16Prev. Close
1211.40
Open Price
1213.70
Bid Price (Qty.)
1209.60 (4)
Offer Price (Qty.)
1210.00 (39)
| Cash Flow of Aurobindo Pharma (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 710.15 | 157.04 | 344.84 | 231.16 | 92.90 | |
| Net CashFlow From Operating Activities | 344.66 | 4.88 | 105.47 | 49.48 | 3.78 | |
| Net Cash Used In Investing Activities | -406.21 | -301.73 | -12.00 | -606.64 | -232.01 | |
| Net Cash Used From Financing Activities | -14.15 | 160.97 | -185.45 | 723.43 | 356.58 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -75.70 | -135.88 | -91.98 | 166.27 | 128.35 | |
| Cash And Cash Equivalents Begin of Year | 79.79 | 209.22 | 298.99 | 144.13 | 13.80 | |
| Cash And Cash Equivalents End Of Year | 4.09 | 73.34 | 207.01 | 310.40 | 142.15 |
19.12.2025
15.12.2025
04.12.2025
23.11.2025
Aurobindo Pharma incurring loss at China Plant; hopes to achieve break-even by Q4
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL